Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity.

Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM, Kedl RM, Kappler JW, Slansky JE.

J Immunol. 2008 Jan 1;180(1):188-97.

2.

Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins.

Jordan KR, Crawford F, Kappler JW, Slansky JE.

Curr Protoc Immunol. 2009 Apr;Chapter 2:Unit 2.15. doi: 10.1002/0471142735.im0215s85.

3.

Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo.

Smyth LA, Hervouet C, Hayday T, Becker PD, Ellis R, Lechler RI, Lombardi G, Klavinskis LS.

J Immunol. 2012 Sep 1;189(5):2274-82. doi: 10.4049/jimmunol.1200664. Epub 2012 Jul 20.

4.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
6.

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM.

J Immunol. 2004 Apr 1;172(7):4215-24.

7.

B lymphocytes participate in cross-presentation of antigen following gene gun vaccination.

Hon H, Oran A, Brocker T, Jacob J.

J Immunol. 2005 May 1;174(9):5233-42.

8.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

9.

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.

Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S.

J Immunol. 2006 Nov 1;177(9):6018-24.

10.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

11.

Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.

Kang TH, Chung JY, Monie A, Pai SI, Hung CF, Wu TC.

Gene Ther. 2010 Apr;17(4):531-40. doi: 10.1038/gt.2009.152. Epub 2009 Nov 26.

12.

The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type.

Smyth LA, Harker N, Turnbull W, El-Doueik H, Klavinskis L, Kioussis D, Lombardi G, Lechler R.

J Immunol. 2008 Sep 1;181(5):3212-20.

13.

Antigen specificity acquisition of adoptive CD4+ regulatory T cells via acquired peptide-MHC class I complexes.

Hao S, Yuan J, Xu S, Munegowda MA, Deng Y, Gordon J, Xing Z, Xiang J.

J Immunol. 2008 Aug 15;181(4):2428-37.

15.

Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.

Ikeuchi N, Futami J, Hosoi A, Noji S, Kurachi M, Ueha S, Fujii S, Yamada H, Matsushima K, Moriyasu F, Kakimi K.

Biochem Biophys Res Commun. 2010 Feb 5;392(2):217-22. doi: 10.1016/j.bbrc.2010.01.019. Epub 2010 Jan 11.

PMID:
20067764
16.

In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.

Cayeux S, Bukarica B, Buschow C, Charo J, Bunse M, Dörken B, Blankenstein T.

Gene Ther. 2007 Oct;14(20):1481-91. Epub 2007 Aug 16.

PMID:
17700709
17.
18.

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.

19.

Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

Watson AM, Mylin LM, Thompson MM, Schell TD.

J Immunol. 2012 Dec 15;189(12):5549-60. doi: 10.4049/jimmunol.1102221. Epub 2012 Nov 21.

20.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
Items per page

Supplemental Content

Write to the Help Desk